ALA · R-ALA · R-Alpha-Lipoic Acid · Thioctic Acid
Alpha-Lipoic Acid (ALA) is a sulfur-containing fatty acid synthesized endogenously in mitochondria, where it serves as an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase - key enzymes in the citric acid cycle. Supplemental ALA exists in both free and protein-bound forms in small amounts in red meat, organ meats, and some vegetables. Endogenous synthesis declines with age.
Take on empty stomach when possible - food reduces absorption by ~30%. 30 minutes before meals or 2 hours after is ideal. Split dosing (morning + afternoon) provides sustained antioxidant coverage.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
ALA functions as a cofactor for mitochondrial dehydrogenase enzymes (pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain alpha-keto acid dehydrogenase), where the disulfide bond is reduced to the dihydrolipoic acid (DHLA) form during catalysis. DHLA is an even more potent antioxidant than ALA itself.
As an antioxidant, ALA directly scavenges reactive oxygen and nitrogen species (hydroxyl radicals, peroxynitrite, singlet oxygen). More uniquely, ALA/DHLA regenerates other antioxidants: reduces oxidized glutathione to GSH, recycles dehydroascorbate to vitamin C, and regenerates tocopherol radicals to vitamin E. This 'antioxidant network' function makes ALA disproportionately valuable vs its plasma levels.
ALA activates AMPK (AMP-activated protein kinase), the cellular energy sensor. AMPK activation increases glucose uptake (via GLUT4 translocation), fatty acid oxidation, and improves insulin sensitivity - mechanisms shared with metformin and berberine. ALA also chelates transition metals (iron, copper, mercury, arsenic), reducing metal-catalyzed oxidative stress.
Peripheral neuropathy benefit likely reflects combined mechanisms: oxidative stress reduction in nerve tissue, improved microvascular blood flow, AGE (advanced glycation end product) inhibition, and direct support of nerve metabolism via cofactor function.
Weeks 1-2: GI adaptation. Subtle energy/mental clarity changes possible.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Dose/route: oral ALA trials included 600 mg/day, matching the top of the card’s 300-600 mg/day range.
A subgroup analysis of the ALA dosage (600, 1200, and 1800 mg/day) was also conducted.
Evidence scope. Human meta-analysis (10 RCTs/1242 patients); diabetic sensorimotor peripheral neuropathy; oral ALA.
Primary safety (route unconfirmed): a Cochrane review of alpha-lipoic acid found probably little or no difference from placebo in adverse events causing treatment discontinuation within six months; the review's own abstract does not state whether the three included trials (816 participants, 6-48 month treatment durations) used oral or intravenous ALA, so this should not be presented as safety data specific to the card's oral regimen without checking the primary trial reports.
There is probably little or no difference between ALA and placebo in terms of adverse events leading to cessation of treatment within six months (risk ratio (RR) 1.48, 95% CI 0.50 to 4.35; 3 studies, 1090 participants; moderate-certainty evidence).
Alpha-lipoic acid for diabetic peripheral neuropathy.
Evidence scope. Human RCTs (3 studies/816 adult participants); diabetic peripheral neuropathy; route of administration not stated in the abstract (oral is plausible given multi-month/year treatment durations, but unconfirmed).
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Mechanism: mitochondrial cofactor/antioxidant mechanism at the displayed oral dose. The selected clinical abstracts establish route, dose, outcomes, and safety, but not the detailed mechanism claimed on the card.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Plasma (rapidly metabolized). Tissue and mitochondrial effects persist longer due to cofactor incorporation.
Fasted, ~2 hours with food.
Most plasma clearance within 3-4 hours. Tissue effects persist 12-24 hours.
Oral: ~30-40% for racemic, ~40-60% for R-ALA. Food reduces absorption by 30%. Fasted dosing significantly better absorbed.
Acute antioxidant effects: ~6-12 hours per dose. Chronic clinical effects (insulin sensitivity, neuropathy) require 4-8 weeks of consistent dosing to manifest.
Extensive hepatic metabolism via beta-oxidation (as a fatty acid) and conversion to DHLA. Renal excretion of metabolites (dihydrolipoate, tetranorlipoate).
Storage. Store at room temperature (20-25C) in a cool, dry place. Protect from moisture and light - ALA is sensitive to both. Capsules shelf-stable 1-2 years; stabilized R-ALA (Na-R-ALA) has longer shelf life than pure R-ALA.
Classified as a dietary supplement in the US. IV form used in hospitals in Germany and other countries for diabetic neuropathy. Not FDA-approved for any medical indication in the US. Widely available over-the-counter.
Put it to work
Open Alpha-Lipoic Acid straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Alpha-Lipoic Acid in the app →Go deeper
The complete Alpha-Lipoic Acid walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.